Novotech

News

High Purity New England Launches Single Use Mixing System

High Purity New England, a leading supplier of biotech equipment and process systems for the Biotech industry, has launched ClearMixx, an innovative single use mixing system. The latest addition to the growing High Purity New England product range, ClearMixx utilizes...

ImmuPharma signs agreement with Avion for Lupuzor

UK-based pharmaceutical company ImmuPharma has signed a licensing and development agreement with US-based Avion Pharmaceuticals for Lupuzor, a peptide therapeutic and a first-in-class autophagy immunomodulator for auto-immune disease systemic lupus erythematosus (SLE or lupus). Under the agreement, the two firms...

Inceptua and Bendalis enter into an exclusive oncology medicine supply agreement for clinical trials

The global pharmaceutical company and service partner Inceptua Group (previously Multipharma GmbH) and Bendalis GmbH โ€“ German manufacturer of generic oncology drugs and special therapeutic agents, announce the signing of an exclusive clinical trial supply agreement for oncology generics. Through...

ERYTECH Announces Publication of its Phase 2b Trial of Eryaspase in Metastatic Pancreatic Cancer in the European Journal of Cancer

ERYTECH Pharma a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced that the full results from its Phase 2b trial evaluating eryaspase in metastatic pancreatic cancer are now published online in...

Chi-Med Announces Surufatinib Granted FDA Orphan Drug Designation for Pancreatic Neuroendocrine Tumors

Hutchison China MediTech Limited announces that the U.S. FDA has granted Orphan Drug designation to surufatinib for the treatment of pancreatic neuroendocrine tumors. โ€œNET is an area of significant unmet medical need. The current treatment options are very limited,โ€ said...

Bayer and Dewpoint Therapeutics partner to research new treatments for cardiovascular and gynecological diseases

Bayer and Dewpoint Therapeutics, a biotechnology company with sites in Boston and Dresden, Germany, announced an option, research and license agreement worth up to USD 100 million. The partnership will leverage Dewpointโ€™s proprietary platform for biomolecular condensates and Bayerโ€™s...

DuPont Reveals Enhanced Application and Innovation Center, Increased Production Capacity at CPhI India

DuPont Nutrition & Biosciences has consistently advanced its customers forward by ensuring global access to indispensable ingredients and unmatched expertise. At CPhI India, Nov. 26-28, the company will showcase increased capacity on both fronts, in addition to several product...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป